Sarepta Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA. 

CEO
Michael E. Severino
CEOMichael E. Severino
Employees
835
Employees835
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1980
Founded1980
Employees
835
Employees835

SRPT Key Statistics

Market cap
1.74B
Market cap1.74B
Price-Earnings ratio
-16.52
Price-Earnings ratio-16.52
Dividend yield
Dividend yield
Average volume
3.11M
Average volume3.11M
High today
$16.76
High today$16.76
Low today
$15.21
Low today$15.21
Open price
$16.43
Open price$16.43
Volume
3.11M
Volume3.11M
52 Week high
$25.32
52 Week high$25.32
52 Week low
$14.68
52 Week low$14.68

Stock Snapshot

With a market cap of 1.74B, Sarepta Therapeutics(SRPT) trades at $16.00. The stock has a price-to-earnings ratio of -16.52.

During the trading session on 2026-08-06, Sarepta Therapeutics(SRPT) shares reached a daily high of $16.76 and a low of $15.21. At a current price of $16.00, the stock is +5.2% higher than the low and still -4.5% under the high.

Trading volume for Sarepta Therapeutics(SRPT) stock has reached 3.11M, versus its average volume of 3.11M.

Over the past 52 weeks, Sarepta Therapeutics(SRPT) stock has traded between a high of $25.32 and a low of $14.68.

Over the past 52 weeks, Sarepta Therapeutics(SRPT) stock has traded between a high of $25.32 and a low of $14.68.

SRPT News

Investing.com 6h
Earnings call transcript: Sarepta beats Q2 2026 estimates as shares rise after hours - Investing.com

...

Earnings call transcript: Sarepta beats Q2 2026 estimates as shares rise after hours - Investing.com
Simply Wall St 7d
Sarepta Therapeutics Could Be 28% Below Fair Value As New CEO Takes Over

Sarepta Therapeutics (SRPT) is back in focus after the board appointed Michael Severino, M.D., as chief executive and director, with his tenure beginning July 2...

Sarepta Therapeutics Could Be 28% Below Fair Value As New CEO Takes Over

Analyst ratings

46%

of 26 ratings
Buy
30.8%
Hold
46.2%
Sell
23.1%

People also own

Based on the portfolios of people who own SRPT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.